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Abstract
Background Pathological complete response (pCR) is the
ultimate response in breast cancer patients treated with
neoadjuvant chemotherapy (NCT). It might be a surrogate
outcome for disease-free survival (DFS) and overall sur-
vival (OS). We studied the effect of clinical tumor stage
(cT-stage) on tumor pCR and the effect of pCR per cT-
stage on 5-year OS and DFS.
Methods Using the Netherlands Cancer Registry, all pri-
mary invasive breast cancer patients treated with NCT
from 2005 until 2008 were identified. Univariable logistic
regression analysis was performed to evaluate the effect of
cT-stage on pCR, stepwise logistic regression analysis to
correct for potential confounders and Kaplan–Meier sur-
vival analyses to calculate OS and DFS after five years.
Results In 2366 patients, overall pCR rate was 21%. For
cT1, cT2, cT3, and cT4, pCR rates were 31, 22, 18, and
17%, respectively. Lower cT-stage (cT1-2 vs cT3-4) was
a significant independent predictor of higher pCR rate
(p\ 0.001, OR 3.15). Furthermore, positive HER2 status
(p\ 0.001, OR 2.30), negative estrogen receptor status
(p = 0.062, OR 1.69), and negative progesterone recep-
tor status (p = 0.008, OR 2.27) were independent pre-
dictors of pCR. OS and DFS were up to 20% higher in
patients with cT2-4 tumors with pCR versus patients
without pCR. DFS was also higher for cT1 tumors with
pCR.
Conclusions The most important predictor of pCR in
breast cancer patients is cT-stage: lower cT-stages have
significantly higher pCR rates than higher cT-stages.
Patients with cT2-4 tumors achieving pCR have higher OS
and DFS compared to patients not achieving pCR.
Keywords Breast cancer  Pathological complete
response  Neoadjuvant chemotherapy  Tumor size 
Survival
Introduction
There is an increase of neoadjuvant chemotherapy (NCT)
administration in breast cancer patients, compared to
adjuvant chemotherapy [1]. The most important aims of
this strategy are to improve surgical safety and to minimize
the extent of the operation by downsizing the tumor. As a
result, breast-conserving surgery rates have increased since
the introduction of NCT [1].
Pathological complete response (pCR), i.e., absence of
any residual cancer, is the ultimate response to NCT in
breast cancer patients. Unfortunately, only 22% of all
patients treated with NCT achieves pCR of the breast
tumor [2]. Patients that achieve pCR show improved sur-
vival rates as compared to patients without pCR for all
subtypes except for low-grade estrogen receptor (ER)-
positive and human epidermal growth factor receptor 2
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(HER2)-negative subtypes [3–11]. Therefore, it is currently
being debated whether pCR can be considered as a surro-
gate outcome for disease-free survival (DFS) and overall
survival (OS) [3].
Ideally, patients achieving pCR should be identified
before NCT administration. This way, determining the
ultimate patient-tailored treatment plan would be possible
at initiation of treatment. For example, the possibility to
perform breast conserving surgery after NCT would be
clear from the start. Currently, we are not able to identify
those patients. Literature shows that high tumor grade,
positive HER2 status, negative ER status, and negative
progesterone receptor (PR) status increase the probability
of achieving pCR [2–6, 12, 13]. With these beneficial
factors to achieve pCR in mind, clinicians can make a
rough estimation of the chance of an individual patient
achieving pCR. However, we need to search for addi-
tional factors that contribute to the fine tuning of this
estimation.
One other factor that might contribute to the probability
of achieving pCR is tumor size. Earlier research of 144
patients treated with NCT between 1975 and 1996 shows
that smaller tumors are more likely to respond to NCT [14].
A study of Bonadonna and colleagues shows that the
degree of response is inversely proportional to the initial
tumor size in tumors larger than three centimeters [15]. The
estimation of pCR chances might therefore be more accu-
rate taking tumor size into account.
The aim of this study was to investigate the effect of
tumor size, expressed as clinical tumor stage (cT-stage), on
pCR with correction for potential confounders like high
tumor grade, positive HER2 status, negative ER status, and
negative PR status. Since it is currently being debated
whether pCR can be considered as a surrogate outcome for
disease-free survival (DFS) and overall survival (OS) in a
selected group of patients, the effect of pCR per cT-stage
on DFS and OS was analyzed as well.
Methods
Study design and patient selection
Using data from the Netherlands Cancer Registry (NCR), a
nationwide, population-based cancer registry managed by
the Netherlands Comprehensive Cancer Organisation
(IKNL), all patients with primary invasive epithelial breast
cancer treated with NCT in the Netherlands between Jan-
uary 2005 and December 2008 were identified and con-
sidered for inclusion. Exclusion criteria were synchronous
breast cancer or distant metastases at time of diagnosis,
previous invasive breast cancer, neoadjuvant radiotherapy,
and neoadjuvant endocrine therapy.
Data collection
The NCR data were retrieved from patients’ records by
trained data registrars. They collected data on patient and
tumor characteristics (age, grade, tumor type, clinical and
pathological TNM-stage, ER, PR, and HER2 status), and
on surgical, radiation and systemic treatment of all new
breast cancer patients directly from the medical records in
all Dutch hospitals. An active follow-up was conducted
registering the first recurrence (local, regional or distant
metastasis) within 5 years after diagnosis. Additional data
on date of death and date of emigration were derived from
the Municipal Personal Records Database, complete until
31 December 2014.
Neoadjuvant systemic treatment, surgical
procedure, and pathological analysis
In addition to neoadjuvant chemotherapy, neoadjuvant
targeted therapy could be administered in case of HER2
receptor amplification (trastuzumab). Furthermore, all
patients underwent surgery of the breast and ipsilateral
axilla. Breast surgery consisted of breast conserving ther-
apy or mastectomy, depending on clinical tumor size,
breast size, and patient preference. Axillary surgery con-
sisted of sentinel lymph node biopsy in case of cN0 and
axillary lymph node dissection in case of cN?. Patholog-
ical analyses of pre-treatment core biopsies and surgically
removed tissue were performed locally in accordance to the
Dutch breast cancer guideline at the time of diagnosis [16].
Patients were classified as positive for ER or PR when
C10% of the tumor cells showed positive nuclear staining
[16, 17].
Objectives and endpoints
Our primary endpoint was complete remission or pCR,
defined as absence of macroscopic and microscopic evi-
dence of invasive tumor in the resected breast tissue (ypT0
or ypTis). In this study, pathological response of the breast
tumor to NCT was studied, not the response of the axillary
lymph nodes. To evaluate the effect of tumor size on pCR,
the parameter cT-stage was used because the exact tumor
diameter on preoperative imaging was not registered.
Secondary endpoints were DFS and OS. DFS is a
composite endpoint consisting of locoregional recurrence,
distant metastases (defined according to the consensus-
based event definitions for recurrence classification of
Moossdorff et al.) [18], contralateral breast cancer, or death
within five years. Survival time was defined as time
between date of diagnosis and any of the above-mentioned
endpoints whichever occurred first. In OS, survival time
was defined as time between date of diagnosis and death.
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For DFS, events occurring within 3 months of date of
diagnosis were considered to be synchronous to the pri-
mary tumor and were not considered to be events.
Statistical analyses
The number of patients achieving pCR per cT-stage and
breast cancer subtype was studied. Univariable logistic
regression was performed to evaluate the effect of lower
cT-stage on pCR and to evaluate the effect of possible
confounders high grade (grade 3 vs grade 1–2), positive
HER2 status, negative ER status, and negative PR status on
pCR. Since not all patients with HER2 amplification
received targeted therapy between 2005 and 2008, a sep-
arate analysis was performed for HER2-positive patients
who received targeted therapy versus those who did not.
Stepwise logistic regression was executed to correct for
possible confounders. Kaplan–Meier survival analyses
were used to calculate OS and DFS. A p value of\0.05
was considered statistically significant. Statistical analyses
were performed using Statistical Package for the Social
Sciences (SPSS), version 22.0 (IBM Corporation, Armonk,
NY, USA).
Results
A total of 2366 primary invasive epithelial breast cancer
patients treated with NCT were included. Baseline char-
acteristics are shown in Table 1.
In 320 patients, clinical and/or pathological tumor stages
were unknown. In 420 of the remaining 2046 patients,
histopathology showed pCR (20.5%). In cT1 patients, 58 of
187 (31.0%) reached pCR, so did 186 of 829 (22.4%) cT2
patients, 94 of 534 (17.6%) cT3 patients, and 82 of 496
(16.5%) cT4 patients. The distribution of breast cancer
subtypes differs slightly per cT-stage, the percentage of the
hormone receptor positive subtypes decreases, and the
percentage of the hormone receptor negative subtypes
increases with higher cT-stage, especially the ER-/PR-/
HER2? subtype increases (Table 2).
In univariable regression analyses, lower cT-stage (cT1-
2 vs cT3-4) was a significant predictor of higher pCR rate
(p\ 0.001). High grade (grade 3 vs grade 1–2)
(p = 0.001), positive HER2 status (p\ 0.001), negative
ER status (p\ 0.001), and PR receptor status (p\ 0.001)
were significant predictors of higher pCR rates as well
(Table 3). Multivariable analysis demonstrated lower cT-
stage, positive HER2 status, and negative PR receptor
status as being independent predictors of pCR. Lower cT-
stage was the most important predictor with an odds ratio
of 3.154 (p\ 0.001) (Table 3).
In 115 out of 669, HER2 positive patients pathological
tumor stage was unknown. Separate analysis of 554
patients with a positive HER2 status showed an overall
pCR rate of 35.6%. In patients receiving NCT including
targeted therapy, this was 47.4% (n = 293) versus 22.2%
in patients not receiving neoadjuvant targeted therapy
added to chemotherapy (n = 261; p\ 0.001). The pCR
rate of patients with a positive HER2 status not receiving
neoadjuvant targeted therapy was higher than pCR rate of
patients with a negative HER2 status (14.9%). The pCR
rate decreased with increasing cT-stage in both subgroups
(Table 4).
Kaplan–Meier survival analyses demonstrated a 5-year
OS of 76.5% for all patients receiving NCT, being 88.2%
for cT1, 84.3% for cT2, 77.0% for cT3, and 58.8% for cT4
tumors. Furthermore, in patients with pCR 5-year OS was
83.8% versus 73.7% without pCR (p\ 0.001). Also, all
separate cT-stages except for cT1 showed a positive effect
of pCR on OS but this difference was only statistically
significant in cT4 (Fig. 1).
Table 1 Baseline characteristics
N (%)
Total number of patients 2366 (100.0)























Hormonal therapy 1393 (58.9)
ER estrogen receptor, PR progesterone receptor, HER2 human epi-
dermal growth factor receptor 2
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Additionally, Kaplan–Meier survival analyses showed
that 5-year DFS was 68.6% for the entire group and 87.3%
for cT1, 75.0% for cT2, 66.6% for cT3, and 55.9% for cT4
tumors. In patients with pCR, 5-year DFS was 79.7%,
without pCR this was 65.0% (p\ 0.001). Furthermore, the
5-year DFS was 9–19% higher in the pCR group versus the
non-pCR group per cT-stage, but this difference was only
statistically significant in cT2 and cT4 (Fig. 2).
Discussion
The primary aim of this study was to investigate the effect
of cT-stage on pCR to analyze if tumor size helps clinicians
estimate pCR chances. Our results demonstrate that lower
cT-stages have significantly higher pCR rates than higher
cT-stages (cT1-2 vs cT3-4; p\ 0.001). In case of cT1,
cT2, cT3, and cT4, pCR rates were 31, 22, 18, and 17%,
respectively. The cT-stage is an independent and stronger
predictor of pCR than ER, PR, and HER2 status and grade.
PCR decreases with increasing cT-stage, even though the
percentage of hormone receptor-negative subtypes (which
respond better to NCT than positive subtypes) increases
with increasing cT-stage. The secondary aim was to ana-
lyze the effect of pCR per cT-stage on DFS and OS. Our
results show that patients with cT2-4 breast tumors and
pCR had an up to 20% higher (disease-free) survival rate
compared to patients without pCR.
To the best of our knowledge, the relation between
breast tumor size and pCR has never been studied before.
An earlier study of Gajdos et al. (n = 138) did demonstrate
that smaller tumors are more likely to respond to
chemotherapy than larger tumors [14], and the study of
Bonadonna et al. (n = 165) showed that the degree of
response is inversely proportional to initial tumor size for
tumors larger than 3 cm [15]. Furthermore, a study by
Caudle and colleagues showed that large tumor size is a
pre-treatment predictor of disease progression [19]. Jin
et al. found that HER2 negative breast cancer patients with
smaller tumor sizes were more likely to achieve pCR than
the ones with larger tumor sizes [20].
The results of our study, which are very much along the
lines of the above described earlier studies, emphasize the
importance for clinicians to take cT-stage into account
Table 2 Pathological tumor response of patients receiving neoadjuvant chemotherapy per clinical tumor stage and per breast cancer subtype
cT-stage N (% of total N per cT-stage) ypT0 or pCR (%) ypT1 (%) ypT2 (%) ypT3 (%) ypT4 (%)
cT1 187 58 (31.0) 108 (57.8) 17 (9.1) 3 (1.6) 1 (0.5)
ER/PR?HER2? 30 (16.0) 14 (46.7)
ER/PR?HER2- 93 (49.7) 12 (12.9)
ER, PR-HER2? 12 (6.4) 6 (50.0)
Triple negative 34 (18.2) 20 (58.8)
Unknown 18 (9.6) 6 (33.3)
cT2 829 186 (22.4) 324 (39.1) 289 (34.9) 24 (2.9) 6 (0.7)
ER/PR?HER2? 123 (14.8) 42 (34.1)
ER/PR?HER2- 419 (50.5) 37 (8.8)
ER-PR-HER2? 77 (9.3) 35 (45.5)
Triple negative 151 (18.2) 60 (39.7)
Unknown 59 (7.1) 12 (20.3)
cT3 534 94 (17.6) 141 (26.4) 176 (33.0) 119 (22.3) 4 (0.7)
ER/PR?HER2? 66 (12.4) 20 (30.3)
ER/PR?HER2- 260 (48.7) 16 (6.2)
ER-PR-HER2? 71 (13.3) 25 (35.2)
Triple-negative 100 (18.7) 26 (26.0)
Unknown 37 (7.0) 7 (18.9)
cT4 496 82 (16.5) 112 (22.6) 126 (25.4) 71 (14.3) 105 (21.2)
ER/PR?HER2? 62 (12.5) 11 (17.7)
ER/PR?HER2- 210 (42.3) 6 (2.9)
ER-PR-HER2? 95 (19.2) 39 (41.1)
Triple-negative 100 (20.2) 21 (21.0)
Unknown 29 (5.9) 5 (17.2)
cT-stage clinical tumor stage, pCR pathologic complete response, ypT0–ypT4 pathological tumor stage after chemotherapy 0 to 4, ER estrogen
receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
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when estimating the chance of pCR in an individual
patient. This study shows for example that a patient with a
triple-negative tumor would have a chance of pCR of
approximately 40% with a cT2 tumor and 26% with a cT3
tumor.
Furthermore, this study encourages clinicians to use
NCT in early-stage breast cancer patients. The current
Dutch guidelines recommend NCT in patients with a tumor
larger than 2 cm or smaller high-risk tumors with as main
goal a safer and less extensive surgery [16]. But as the
oncologic field moves toward minimally invasive surgery
or even watchful waiting [21, 22], breast cancer patients
especially with small tumors (cT1-2) and higher chances of
attaining pCR might be the perfect candidates for safe
watchful waiting in the future. Future research goals are
therefore to explore the possibilities for safe watchful
waiting in breast cancer patients that achieve pCR and
therewith to search for an imaging technique that is good
enough to estimate the precise residual tumor size and
predict pCR [23].
Table 3 Univariable and
multivariable analysis of
predictors of pathologic









95% CI for OR
Lower Upper
cT-stage
1–2 24.0 \0.001 \0.001 3.154 2.027 4.907
3–4 17.1
Grade
3 20.0 0.001 0.177 1.383 0.864 2.214
1–2 11.4
ER
Neg 36.3 \0.001 0.062 1.687 0.974 2.920
Pos 12.0
PR
Neg 29.3 \0.001 0.008 2.269 1.243 4.141
Pos 12.0
HER2
Pos 35.6 \0.001 \0.001 2.299 1.493 3.540
Neg 14.9
pCR pathologic complete response, OR odds ratio, cT-stage clinical tumor stage, ER estrogen receptor, PR
progesterone receptor, HER2 human epidermal growth factor receptor 2
Table 4 Number of HER2-
positive breast cancer patients
treated with versus without
neoadjuvant targeted therapy
that has pathologic complete
response per tumor stage
cT-stage N pCR/total with TT (%) N pCR/total without TT (%)
cT1 11/20 (55.0) 9/22 (40.9)
ER/PR? 8/14 6/16
ER-, PR- 3/6 3/6
cT2 58/117 (49.6) 19/87 (21.8)
ER/PR? 30/67 12/56
ER-, PR- 28/49 7/28
cT3 29/66 (43.9) 18/74 (24.3)
ER/PR? 12/30 8/36
ER-, PR- 16/34 9/37
cT4 40/87 (46.0) 10/73 (13.7)
ER/PR? 8/26 3/36
ER-, PR- 32/58 7/37
cTx 1/3 (33.3) 2/5 (40.0)
Total 139/293 (47.4) 58/261 (22.2)
cT-stage clinical tumor stage, pCR pathological complete response, TT targeted therapy, ER estrogen
receptor, PR progesterone receptor
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Fig. 1 Kaplan–Meier curves 5-year overall survival of patients with versus without pathologic complete response per clinical tumor stage.
cT(-stage) clinical tumor stage, pCR pathological complete response
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Fig. 2 Kaplan–Meier curves of five year disease-free survival of patients with versus without pathologic complete response per clinical tumor
stage. cT(-stage) clinical tumor stage, pCR pathological complete response
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Multiple (retrospective) studies demonstrated that pCR
can be used as surrogate outcome for OS and DFS [4–8]
The recent meta-analysis of Cortazar analyzed the effect of
pCR between treatment groups on event-free survival
(EFS) and OS [3]. They found an association between pCR
and improved EFS and OS but an increase in frequency of
pCR between treatment groups could not be validated as a
surrogate endpoint for improved EFS and OS. This may be
explained by the heterogeneity of the treatment regimens in
the studies in this meta-analysis, obscuring the association
between pCR and survival.
In our study, patients with pCR of the breast tumor had
an up to 20% higher (disease-free) survival rate compared
to patients without pCR. This positive effect of pCR on
5-year OS was not present for cT1 tumors and only sta-
tistically significant in cT2 (DFS) and cT4 (DFS and OS)
tumors. One potential explanation is that the prognosis of
most cT1 breast tumors is already so favorable that their
benefit of achieving pCR is only small. Another potential
explanation which especially accounts for cT1 tumors is
that selection for NCT probably differs from cT2-4
tumors, and it concerns only a small group of patients. In
cT1 tumors, the choice to start NCT will more often be
based on the presence of tumor positive lymph nodes,
HER2 amplification or their triple-negative character; in
the other groups, this choice will be more often based on
tumor size, making it prognostically different subgroups.
Patients with tumor-positive lymph nodes, amplification
of HER2, or a triple-negative tumor have a worse prog-
nosis than patients without these traits. Furthermore,
looking at our Kaplan–Meier curves, we expect survival
differences between patients achieving versus not
achieving pCR only to increase by the years and 10-year
survival differences to be statistically significant for all
cT-stages. This should be investigated in future research.
Nevertheless, achieving pCR will not entirely eliminate
recurrence.
Our study was limited by its retrospective design.
Chemotherapy regimens can affect pCR rate [5, 24].
Unfortunately, the exact regimens (number of treatments,
dosages) were not registered in the NCR. Furthermore,
because tumor grade often was unknown, this may have
influenced the prognostic value of tumor grade or other
factors in the multivariable analysis. Finally, in situ com-
ponents in the resected tissue were not coded. Therefore,
pCR was defined as no microscopic evidence of invasive
tumor in our study. According to the literature, there might
be a small difference in prognosis between patients with
and without in situ components after NCT but this could
not be studied [7].
In conclusion, the most important predictor of pCR is
the cT-stage: lower cT-stages have significantly higher
pCR rates than higher cT-stages, independent of grade, ER,
PR, and HER2 status. Furthermore, 5-year OS and DFS
were up to 20% higher in patients with cT2–cT4 tumors
with pCR versus patients without pCR.
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